ClinicalTrials.gg
Status unknownNCT04885361COVEPIT 3Updated Jun 9, 2021

To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults

A Phase 1 interventional study of CoVepiT (OSE13E) in Coronavirus Disease (COVID-19), sponsored by OSE Immunotherapeutics. Status unknown at 1 site in Belgium. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by OSE Immunotherapeutics · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in COVID-19 with a site in Belgium — 11 open to participants now, 16 under way, 6 of them phase 3. COVID-19 · Belgium.

Planned enrollment
75th of 103
48 · median 150
Started
2021
with 44 others
Phase 1
14 of 173
none open now
Registered
121st of 173
by date

Among the 173 studies in COVID-19 with a site in Belgium, this one is the 75th largest by planned enrollment of the 103 interventional ones that give a count, is one of 45 that started in 2021, is one of 14 in phase 1, and was the 121st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

11 of the 173 studies in COVID-19 with a site in Belgium are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in COVID-19 with a site in Belgium, or all of them as a file.
02

Study summary

The proposed study is a phase 1 study which will evaluate the safety, reactogenicity and immunogenicity of two doses regimen of CoVepiT vaccine (OSE-13E) in the population of n=48 healthy volunteers 18 to 45 (inclusive) years old, vaccinated or not by authorized COVID-19 vaccine.

Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

First 4 subjects will serve as sentinel cohort and 7 days reactogenicity data of these subjects will be reviewed by the independent safety monitoring committee (SMC) before proceeding to the vaccination of remaining volunteers. The progress of the study will be overviewed by a safety monitoring committee (SMC).

The CoVepiT vaccine is a peptide-based vaccine aiming to induce CD8+T-cell-mediated immune response against 11 different proteins of SARS-CoV-2 virus.

03

Conditions studied

  • Coronavirus Disease (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject's meeting all the following criteria are eligible to participate in this study:

  • Males or females 18 to 45 (inclusive) years of age, at screening.
  • Healthy participants as determined based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • Subjects not previously vaccinated with any COVID-19 vaccine OR Subjects who have completed the vaccination according to an officially accepted scheme (e.g., healthcare workers), at least 4 weeks prior to enrollment, with an authorized vaccine which induces neutralizing antibodies against the SARS-CoV-2 Spike protein.
  • Willing and able to give .
  • Willing to accept following measures:

Exclusion criteria

Exclusion Criteria:

  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition, including but not limited to any of the following conditions that are risk factors of severe illness from the virus that causes COVID-19:

    • Active cancer () within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
    • Chronic kidney disease
    • Moderate to severe asthma
    • Current tobacco smoking
    • People who have had an organ transplant.
    • Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
    • ≥ 30 kg/m2 or BMI \<17 kg/m2
    • Type 2 diabetes mellitus
    • Chronic liver disease
    • Sickle cell disease Hypertension
  • Type 1 diabetes
  • Known infection with (HIV), virus (HCV), or virus (HBV).
  • Participation in research involving an product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS, MERS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure during 2-4 weeks prior to enrollment to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
  • Professionals involved in direct care of the COVID-19 patients and with a high risk of exposure to SARS-CoV-2 (i.e., healthcare worker of intensive care unit at infectology department ).
  • Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
  • Positive rapid test for SARS-CoV-2 (ELISA or PCR) at screening or prior to first vaccination.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination. NOTE: COVID-19 marketed vaccines may be allowed as long inclusion criterion #3 is met.
  • Any or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of , systemic glucocorticosteroids, or other immune-modifying drugs within 4 months prior to first study vaccination or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of ≥38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) (ie, cough, sore throat, difficulty breathing)
  • Known disturbance of coagulation (iatrogenic or congenital). NOTE: The use of ≤325 mg of aspirin per day as prophylaxis is permitted, but the use of other aggregation inhibitors, thrombin inhibitors, Factor Xa inhibitors, or warfarin derivatives is exclusionary, regardless of bleeding history, because these imply treatment or prophylaxis of known cardiac or vascular disease.
  • Any neurological disease or history of significant neurological disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  • Vital sign (blood pressure, pulse, temperature) abnormalities of toxicity grade >1
  • Clinical laboratory abnormalities of toxicity grade >1 for selected serum chemistry and hematology parameters
  • Any known allergies to products contained in the investigational product or latex allergy, or history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
  • Women who are pregnant, breastfeeding or who plan to become pregnant during the study.
  • History of alcohol abuse or drug addiction within one year prior to the first study vaccination.
  • Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  • Study team member or first-degree relative of any study team member (inclusive of sponsor or delegate, and site personnel involved in the study).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Arm 1 injection

    The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.

    Biological: CoVepiT (OSE13E)

  • Experimental
    Arm 2 injections separated by 21 days

    The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.

    Biological: CoVepiT (OSE13E)

Interventions

  • BiologicalCoVepiT (OSE13E)

    Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

06

What researchers measure

Primary outcomes

  1. The incidence of solicited local reactogenicity signs and symptoms

    Time frame: up to 7 days after each injection

  2. The incidence of solicited systemic reactogenicity signs and symptoms

    Time frame: up to 7 days after each injection

  3. The incidence of unsolicited adverse events in study participants.

    Time frame: up to 28 days after each vaccination.

  4. The occurrence of serious adverse events (SAE).

    Time frame: throughout study completion, an average of 6 months.

  5. The occurrence of adverse events of special interest (AESI), including potentially immune mediated disorders (pIMD)

    Time frame: throughout study completion, an average of 6 months.

  6. Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes at Week 6 - 1 versus 2 doses

    Time frame: Week 6

Secondary outcomes

  1. Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes

    Time frame: Day 22, Month 3 and Month 6

  2. Geometric mean fold rise of CD8+ T cells responding to SARS-CoV-2 wild type

    Time frame: Day 22, Month 3 and Month 6

  3. Proportion of participants achieving ≥2-fold rise of secreting spots specific to SARS-CoV-2 wild type epitopes

    Time frame: At baseline and after each vaccination

  4. Change in geometric mean count (GMC) of CD8+ T cells antigen specific to SARS-CoV-2 wild type epitopes

    Time frame: from the pre-injection baseline (Day 1) to Day 22, Week 6, Month 3 and Month 6

07

Study locations

1 of 1 sites recruiting
  • Center for Vaccinology (CEVAC),
    Gent, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Sep 2021, 4 months after the start.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's planned 4 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2021
First posted
May 13, 2021
StartActual
May 26, 2021
Primary completionEst.
Sep 30, 2021
CompletionEst.
Mar 31, 2022
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04885361
Lead sponsor
OSE Immunotherapeutics
Responsible party
Sponsor
First posted
May 13, 2021
Start date
May 26, 2021
Primary completion
Sep 30, 2021 (estimated)
Completion
Mar 31, 2022 (estimated)
Last update
Jun 9, 2021

Study contacts

Ose immunotherapeutics
Contact
contact@ose-immuno.com
01 43 29 78 57

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion